| ADC | Antibody–drug conjugate |
| AKT | Protein kinase B |
| AP-1 | Activator protein 1 |
| APOBEC3A | Apolipoprotein B mRNA editing enzyme catalytic subunit 3A |
| CAF | Cancer-associated fibroblast |
| CDK2 | Cyclin-dependent kinase 2 |
| CDK4/6 | Cyclin-dependent kinases 4 and 6 |
| CDK4/6i | CDK4/6 inhibitor(s) |
| CITUP | Clonal inference in tumors using phylogeny |
| CODEX | CO-Detection by indEXing |
| CSC | Cancer stem cell |
| ctDNA | Circulating tumor DNA |
| DCIS | Ductal carcinoma in situ |
| DNA | Deoxyribonucleic acid |
| DNMT | DNA methyltransferase |
| DTP | Drug-tolerant persister |
| ECM | Extracellular matrix |
| EGFR | Epidermal growth factor receptor |
| EMT | Epithelial-to-mesenchymal transition |
| ER | Estrogen receptor |
| ER+ | Estrogen receptor-positive |
| ET | Endocrine therapy |
| EZH2 | Enhancer of zeste homolog 2 |
| FAD | Flavin adenine dinucleotide |
| FAO | Fatty acid oxidation |
| FGFR | Fibroblast growth factor receptor |
| GPX4 | Glutathione peroxidase 4 |
| H3K4me3 | Histone H3 lysine 4 trimethylation |
| H3K27me3 | Histone H3 lysine 27 trimethylation |
| H4K20me3 | Histone H4 lysine 20 trimethylation |
| HDAC | Histone deacetylase |
| HER2 | Human epidermal growth factor receptor 2 |
| HER2+ | HER2-positive |
| HGF | Hepatocyte growth factor |
| HIF-1α | Hypoxia-inducible factor 1 alpha |
| HLA-G | Human leukocyte antigen G |
| HMOX1 | Heme oxygenase 1 |
| ICI | Immune checkpoint inhibitor |
| IGF-1R | Insulin-like growth factor 1 receptor |
| IL-6 | Interleukin 6 |
| IL-10 | Interleukin 10 |
| IMC | Imaging mass cytometry |
| ISR | Integrated stress response |
| ITH | Intra-tumoral heterogeneity |
| JAK | Janus kinase |
| KDM5A/B | Lysine demethylase 5A/B (JARID1A/B) |
| KDM6A/B | Lysine demethylase 6A/B |
| KRT5/14/17 | Keratin 5/14/17 |
| LAM | Lipid-associated macrophage |
| LSD1 | Lysine-specific demethylase 1 (KDM1A) |
| MAPK | Mitogen-activated protein kinase |
| MDR1 | Multidrug resistance protein 1 (P-glycoprotein) |
| MERFISH | Multiplexed error-robust fluorescence in situ hybridization |
| MET | Mesenchymal–epithelial transition factor (hepatocyte growth factor receptor) |
| MHC | Major histocompatibility complex |
| MOFA+ | Multi-Omics Factor Analysis |
| MPC | Metastatic precursor cell |
| mTOR | Mechanistic target of rapamycin |
| NF-κB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| NRF2 | Nuclear factor erythroid 2-related factor 2 (NFE2L2) |
| OXPHOS | Oxidative phosphorylation |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed death-ligand 1 |
| PDX | Patient-derived xenograft |
| P-gp | P-glycoprotein (MDR1/ABCB1) |
| PI3K | Phosphatidylinositol 3-kinase |
| PINK1 | PTEN-induced kinase 1 |
| PIK3CA | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| PRC2 | Polycomb repressive complex 2 |
| RB1 | Retinoblastoma protein 1 |
| RNA | Ribonucleic acid |
| ROS | Reactive oxygen species |
| RTK | Receptor tyrosine kinase |
| SAM | S-adenosylmethionine |
| scATAC-seq | Single-cell assay for transposase-accessible chromatin sequencing |
| scCUT&Tag | Single-cell cleavage under targets and tagmentation |
| scRNA-seq | Single-cell RNA sequencing |
| SLC7A11 | Solute carrier family 7 member 11 (xCT) |
| ST | Spatial transcriptomics |
| STAT3 | Signal transducer and activator of transcription 3 |
| TAM | Tumor-associated macrophage |
| TCA | Tricarboxylic acid |
| T-DXd | Trastuzumab deruxtecan |
| TER | Tumor clonal evolution rate |
| TGF-β | Transforming growth factor beta |
| TIGIT | T-cell immunoreceptor with Ig and ITIM domains |
| TIM-3 | T-cell immunoglobulin and mucin domain-containing protein 3 |
| TME | Tumor microenvironment |
| TNBC | Triple-negative breast cancer |
| VAF | Variant allele frequency |
| WNN | Weighted nearest neighbor |
| xCT | Cystine/glutamate antiporter (SLC7A11) |
| α-KG | Alpha-ketoglutarate |